# Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

> **NCT04186871** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 119 (actual)

## Conditions studied

- Autoimmune Disorder
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Primary Sjögren's Syndrome

## Interventions

- **DRUG:** branebrutinib
- **DRUG:** abatacept
- **DRUG:** branebrutinib placebo

## Key facts

- **NCT ID:** NCT04186871
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-07
- **Primary completion:** 2022-12-05
- **Final completion:** 2022-12-05
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04186871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04186871, "Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04186871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*